Chapter 21 Cutaneous photosensitivity and photoprotection for photodynamic therapy patients

Comprehensive Series in Photosciences

Volumn 2, Issue C, 2001, Pages 321-337

  Trehan, Manju ^a   Taylor, Charles R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44949110659     PISSN: 1568461X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1568-461X(01)80125-3     Document Type: Article

References (59)

1. Lui H., and Anderson R.R. Photodynamic therapy in dermatology: recent developments. Dermatol. Clin. 11 (1993) 1-13
2. Ortel B., Calzavara-Pinton P.G., Szeimies R.M., and Hasan T. Perspectives in cutaneous photodynamic sensitization. J. Photochem. Photobiol. B 36 (1996) 209-211
3. Harty J.I., Amin M., Wieman T.J., Tseng M.T., Ackerman D., and Broghamer W. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J. Urol. 141 (1989) 1341-1346
4. Davis R.K., Straight R., and Kereszti Z. Comparison of photosensitizers in saline and liposomes for tumor photodynamic therapy and skin phototoxicity. Laryngoscope 100 (1990) 682-686
5. Mukhtar H., Agarwal R., Athar M., Lewen R.L., Elmets C.A., and Bickers D.R. Photodynamic therapy of murine skin tumors using Photofrin-II. PhotoDermatol. Photoimmunol. Photomed. 8 (1991) 169-175
6. Levy J.G. Photosensitizers in photodynamic therapy. Semin. Oncol. 21 (1994) 4-10
7. Bellnier D.A., and Dougherty T.J. A preliminary pharmacokinetic study of intravenous Photofrin in patients. J. Clin. Laser Med. Surg. 14 (1996) 311-314
8. Bellnier D.A., and Dougherty T.J. The time course of cutaneous porphyrin photosensitization in the murine ear. Photochem. Photobiol. 49 (1989) 369-372
9. Calzavara-Pinton P.G., Szeimies R.M., Ortel B., and Zane C. Photodynamic therapy with, systemic administration of photosensitizers in dermatology. J. Photochem. Photobiol. B. 36 (1996) 225-231
10. Schuitmaker J.J., Baas P., van Leengoed H.L., van der Meulen F.W., Star W.M., and van Zandwijk N. Photodynamic therapy: a promising new modality for the treatment of cancer. J. Photochem. Photobiol. B. 34 (1996) 3-12
11. Menter J.M., Hollins T.D., Sayre R.M., Etemadi A.A., Willis I., and Hughes S.N. Protection against photodynamic therapy (PDT)-induced photosensitivity by fabric materials. Photodermatol. Photoimmunol. Photomed. 14 (1998) 154-159
12. Mlkvy P., Messmann H., Regula J., Conio M., Pauer M., Millson C.E., MacRobert A.J., and Bown S.G. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. Neoplasma 42 (1995) 109-113
13. Rhodes L.E., Tsoukas M.M., Anderson R.R., and Kollias N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J. Invest. Dermatol. 108 (1997) 87-91
14. Sacchini V., Melloni E., Marchesini R., Fabrizio T., Cascinelli N., Santoro O., Zunino F., Andreola S., and Bandieramonte G. Topical administration of tetrasodium-meso-tetraphenylporphinesulfonate (TPPS) and red light irradiation for the treatment of superficial neoplastic lesions. Tumori 73 (1987) 19-23
15. Lapes M., Petera J., and Jirsa M. Photodynamic therapy of cutaneous metastases of breast cancer after local application of meso-tetra-(para-sulphophenyl)-porphin (TPPS4). J. Photochem. Photobiol. B. 36 (1996) 205-207
16. Tsoukas M.M., Lin G.C., Lee M.S., Anderson R.R., and Kollias N. Predictive dosimetry for threshold phototoxicity in photodynamic therapy on normal skin: red wavelengths produce more extensive damage than blue at equal threshold doses. J. Invest. Dermatol. 108 (1997) 501-505
17. Tsoukas M.M., Gonzalez S., Flotte T.J., Anderson R.R., Sherwood M.E., and Kollias N. Wavelength and fluence effect on vascular damage with photodynamic therapy on skin. J. Invest. Dermatol. 114 (2000) 303-308
18. Lin G.C., Tsoukas M.L., Lee M.S., Gonzalez S., Vibhagood C., Anderson R.R., and Kollias N. Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy. Photochem. Photobiol. 68 (1998) 575-583
19. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Semin. Oncol. 21 (1994) 11-14
20. Ris H.B., Krueger T., Giger A., Lim C.K., Stewart J.C., Althaus U., and Altermatt H.J. Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts. Br. J. Cancer 79 (1999) 1061-1066
21. Wagnieres G., Hadjur C., Grosjean P., Braichotte D., Savary J.F., Monnier P., and van den Bergh H. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin. Photochem. Photobiol. 68 (1998) 382-387
22. Grosjean P., Savary J.F., Mizeret J., Wagnieres G., Woodtli A., Theumann J.F., Fontolliet C., Van den Bergh H., and Monnier P. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. J. Clin. Laser Med. Surg. 14 (1996) 281-287
23. Savary J.F., Monnier P., Fontolliet C., Mizeret J., Wagnieres G., Braichotte D., and van den Bergh H. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Arch. Otolaryngol Head Neck Surg. 123 (1997) 162-168
24. Hettiaratchy S., Clarke J., Taubel J., and Besa C. Burns after photodynamic therapy. Br. Med. J. 320 (2000) 1245
25. Bryce R. Burns after photodynamic therapy. Drug point gives misleading impression of incidence of burns with temoporfin (Foscan). Br. Med. J. 320 (2000) 1731-1732
26. [published erratum appears in Photochem. Photobiol., 50(6), 1 (Dec. 1989)]. Kessel D. Determinants of photosensitization by mono-L-aspartyl chlorin e6. Photochem. Photobiol. 49 (1989) 447-452
27. Kessel D., Whitcomb K.L., and Schulz V. Lipoprotein-mediated distribution of N-aspartyl chlorin-E6 in the mouse. Photochem. Photobiol. 56 (1992) 51-56
28. Ferrario A., Kessel D., and Gomer C.J. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. Cancer Res. 52 (1992) 2890-2893
29. Gomer C.J., and Ferrario A. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. Cancer Res. 50 (1990) 3985-3990
30. Roberts W.G., Smith K.M., McCullough J.L., and Berns M.W. Skin photosensitivity and photodestruction of several potential photodynamic sensitizers. Photochem. Photobiol. 49 (1989) 431-438
31. Taber S.W., Fingar V.H., Coots C.T., and Wieman T.J. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. Clin. Cancer Res. 4 (1998) 2741-2746
32. Kalka K., Merk H., and Mukhtar H. Photodynamic therapy in dermatology. J. Am. Acad. Dermatol. 42 (2000) 389-413
33. Mang T.S., Allison R., Hewson G., Snider W., and Moskowitz R. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J. Sci. Am. 4 (1998) 378-384
34. Fickweiler S., Abels C., Karrer S., Baumler W., Landthaler M., Hofstadter F., and Szeimies R.M. Photosensitization of human skin cell lines by ATMPn (9-acetyoxy-2,7,12,17-tetrakis-(beta-methoxyethyl)porphycene) in vitro: mechanism of action. J. Photochem. Photobiol. B 48 (1999) 27-35
35. Karrer S., Abels C., Szeimies R.M., Baumler W., Dellian M., Hohenleutner U., Goetz A.E., and Landthaler M. Topical application of a first porphycene dye for photodynamic therapy-penetration studies in human perilesional skin and basal cell carcinoma. Arch. Dermatol. Res. 289 (1997) 132-137
36. Abels C., Szeimies R.M., Steinbach P., Richert C., and Goetz A.E. Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene. J. Photochem. Photobiol. B 40 (1997) 305-312
37. Oleinick N.L., Antunez A.R., Clay M.E., Rihter B.D., and Kenney M.E. New phthalocyanine photosensitizers for photodynamic therapy. Photochem. Photobiol. 57 (1993) 242-247
38. Tralau C.J., Barr H., Sandeman D.R., Barton T., Lewin M.R., and Bown S.G. Aluminum sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas. Photochem. Photobiol. 85 (1987) 443-456
39. Ometto C., Fabris C., Milanesi C., Jori G., Cook M.J., and Russell D.A. Tumour-localising and-photosensitising properties of a novel zinc(II) octadecylphthalocyanine. Br. J. Cancer 74 (1996) 1891-1899
40. Anderson C., Hrabovsky S., McKinley Y., Tubesing K., Tang H.P., Dunbar R., Mukhtar H., and Elmets C.A. Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression. Photochem. Photobiol. 65 (1997) 895-901
41. Anderson C.Y., Freye K., Tubesing K.A., Li Y.S., Kenney M.E., Mukhtar H., and Elmets C.A. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice. Photochem. Photobiol. 67 (1998) 332-336
42. Cincotta L., Foley J.W., MacEachern T., Lampros E., and Cincotta A.H. Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res. 54 (1994) 1249-1258
43. Cincotta L., Szeto D., Lampros E., Hasan T., and Cincotta A.H. Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem. Photobiol. 63 (1996) 229-237
44. Sessler J.L., and Miller R.A. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol. 59 (2000) 733-739
45. Young S.W., Woodburn K.W., Wright M., Mody T.D., Fan Q., Sessler J.L., Dow W.C., and Miller R.A. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem. Photobiol. 63 (1996) 892-897
46. Taylor C.R., Kwangsukstith C., Wimberly J., Kollias N., and Anderson R.R. Turbo-PUVA: dihydroxyacetone-enhanced photochemotherapy for psoriasis: a pilot study. Arch. Dermatol. 135 (1999) 540-544
47. Raab W.P., Tronnier H., and Wiskemann A. Photoprotection and skin coloring by oral carotenoids. Dermatologica 171 (1985) 371-373
48. Alcaraz M.V., Pathak M.A., Rius F., Kollias N., and Gonzalez S. An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model. A pilot study. Photodermatol. Photoimmunol. Photomed. 15 (1999) 120-126
49. Webber J., Kessel D., and Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J. Surg. Res. 68 (1997) 31-37
50. Murphy G.M. Evaluation of porphyria. Photodermatol. Photoimmunol. Photomed. 14 (1998) 58-63
51. Paslin D.A. The porphyrias. Int. J. Dermatol. 31 (1992) 527-539
52. Todd D.J. Erythropoietic protoporphyria. Br. J. Dermatol. 131 (1994) 751-766
53. Corbett M.F., Herxheimer A., Magnus I.A., Ramsay C.A., and Kobza-Black A. The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br. J. Dermatol. 97 (1977) 655-662
54. Bijlmer-Iest J.C., Baart de la Faille H., van Esbeck B.S., van Hattum J., van Weelden H., Marx J.J., and Koningsberger J.C. Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine. Photodermatol. Photoimmunol. Photomed. 9 (1992) 245-249
55. Ray R.S., and Joshi P.C. Protection of UV-radiation induced skin toxicity by reactive oxygen scavengers. Indian J. Exp. Biol. 33 (1995) 383-386
56. Sayre R.M., and Black H.S. Beta-carotene does not act as an optical filter in skin. J. Photochem. Photobiol. B 12 (1992) 83-90
57. McLear P.W., and Hayden R.E. Prevention of cutaneous phototoxicity in photodynamic therapy. Am. J. Otolaryngol. 10 (1989) 92-98
58. Hogikyan N.D., Hayden R.E., and McLear P.W. Cutaneous photoprotection using a hydroxyl radical scavenger in photodynamic therapy. Am. J. Otolaryngol. 12 (1991) 1-5
59. Baas P., van Geel I.P., Oppelaar H., Meyer M., Beynen J.H., van Zandwijk N., and Stewart F.A. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br. J. Cancer 73 (1996) 945-951